Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Arch Biopartners Inc
V.ARCH
Alternate Symbol(s):
ACHFF
Technology
Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok...
). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:ARCH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(54)
•••
GoldenArm
X
View Profile
View Bullboard History
Post by
GoldenArm
on Dec 31, 2021 10:05am
Apology to Riverfolk
Riverfolk, I thought you had bailed when the news came out, based on my previous experience in other stocks and pumpers, but now I see the error in that call. I apologize for my comments and now I
...more
(54)
•••
GoldenArm
X
View Profile
View Bullboard History
Comment by
GoldenArm
on Dec 31, 2021 10:03am
RE:RE:RE:RE:Nobody else seems concerned AT ALL
Hey Bear, I haven't been on the board for awhile because of health issues and slowly getting back to normal.
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Dec 30, 2021 9:28pm
ARCH - Sepsis-Induced Inflammation & AKI inhibited by LSALT
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Dec 30, 2021 9:26pm
ARCH - Metablok Preserves Kidney Function
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Dec 30, 2021 9:25pm
Just Remember River. It was YOU who randomly attacked AGN.
You attacked a company not even competing with arch. Are you in the DMT/Stroke psychedelic space? Are you in the Chronic Cough space? Are you in the Small Cell Lung Cancer space? Are you in the
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Dec 30, 2021 9:24pm
ARCH - Dipeptidase-1 and the Kidney
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Dec 30, 2021 8:49pm
Arch - Novel Therapeutic Developers Explain Technology
Overview of the LSALT Peptide Program
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Dec 30, 2021 8:41pm
ARCH - Intellectual Property
Intellectual Property MetaBlok was invented by Arch scientists Dr. Stephen Robbins, Dr. Donna Senger, Dr. Jennifer Rahn and their University of Calgary colleague, Dr. Paul Kubes. The inventors have
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Dec 30, 2021 8:40pm
Yeah River. Those same talking point were debunked at CEO.CA
You were provided with a list of 22 Patents by Algernon which includes the Chronic Cough. I need not spam your coveted little message board with the particulars. You can catch up after the uplist to
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Dec 30, 2021 8:37pm
ARCH - FULLY FUNDED PHASE III
Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Dec 30, 2021 8:36pm
ARCH -Third Party Validation of Mechanism of Action
Dipeptidase-1
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Dec 30, 2021 8:34pm
Arch Biopartners - My Due Diligence (NEW)
Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch is
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Dec 30, 2021 8:31pm
ARCH - Minister Copping
“The drug candidate from Arch Biopartners, which has the generic name LSALT peptide, was discovered by @UCalgary scientists about five years ago.” https://twitter.com/JasonCoppingAB/status
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Dec 30, 2021 8:29pm
ARCH - PM Justin Trudeau
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Why the Tonopah Gold Project is One to Watch
Targeting Nevada and Ontario for the Critical Minerals Supply Chain
Asset Sale Allows Biotech Company to Refocus on the High Value Dermatological Market
Positive PEA for Uranium-Vanadium Deposit After-tax NPV 8%: $227.7 million with IRR: 38.9%
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Q Precious & Battery Metals Contracts First Class Drilling for Quebec Projects